Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery

Cell Cycle

Volumn 9, Issue 6, 2010, Pages 1104-1111

  Popowicz, Grzegorz M ^a   Czarna, Anna ^a   Wolf, Siglinde ^a   Wang, Kan ^b   Wang, Wei ^b   Dömling, Alexander ^b   Holak, Tad A ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cancer; Drug design; MDM2; MDMX; p53; Structure

Indexed keywords

INDOLE DERIVATIVE; MI 63; NUTLIN 3; OXINDOLE; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; UNCLASSIFIED DRUG; WK 23; WK 298;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; FLUORESCENCE ANALYSIS; IC 50; LIGAND BINDING; POLARIZATION; PROTEIN PROTEIN INTERACTION; STRUCTURE ANALYSIS;

EID: 77953492371     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.6.10956     Document Type: Article

References (43)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10.
2. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6:909-23.
3. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biot 2006; 8:275-83.
4. Marine JCW, Dyer MA, Jochemsen AG. MDMX: from bench to bedside. J Cell Sci 2007; 120:371-8.
5. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Ann Rev Bioch 2008; 77:557-82.
6. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Disc 2008; 7:979-87.
7. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69:1237-45.
8. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-9.
9. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303.
10. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007; 13:23-31.
11. Murray JK, Gellman SH. Targeting protein-protein interactions: Lessons from p53/MDM2. Biopolymers 2007; 88:657-86.
12. Dömling A. Small molecular weight protein-protein interaction antagonists - an insurmountable challenge? Curr Opin Chem Biol 2008; 12:281-91.
13. Bixby D, Kujawski L, Wang S, Sami N, Malek SN. The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis. Cell Cycle 2008; 7:971-9.
14. Cheok CF, Lane DP. New developments in small molecules targeting p53 pathways in anticancer therapy. Drug Dev Res 2008; 69:289-96.
15. Shangary S, Wang SM. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2008; 49:223-41.
16. Shangary S, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008; 105:3933-8.
17. Meulmeester E, Jochemsen AG. p53: A guide to apoptosis. Curr Cancer Drug Targ 2008; 8:87-97.
18. Lehman JA, Eitel JA, Batuello CN, Mayo LD. Therapeutic considerations for Mdm2: not just a one trick pony. Expert Opin Drug Dicov 2008; 3:1309-21.
19. Wade M, Wahl GM. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 2009; 7:1-11.
20. Macchiarulo A, Pellicciari R. MDM2/MDMX inhibitor peptide: WO2008106507. Expert Opin Therap Pat 2009; 19:721-6.
21. Marx J. Recruiting the cell's own guardian for cancer therapy. Science 2007; 315:1211-3.
22. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127:1323-34.
23. Ventura A, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445:661-5.
24. Xue W, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445:656-60.
25. Laurie NA, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444:61-6.
26. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM. Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 2006; 281:33036-44.
27. Doemling A. Selective and dual-action p53/mdm2/mdm4 antagonists. WO 2008130614.
28. Bassett EA, Wang W, Rastinejad F, El-Deiry WS. Structural and functional basis for therapeutic modulation of p53 signaling. Clin Cancer Res 2008; 14:6376-86.
29. Vassilev LT, et al. In vivo activation of the p53 pathway by small-molecular antagonists of Mdm2. Science 2004; 303:844-8.
30. Grasberger BL, et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 2005; 48:909-12.
31. Popowicz GM, et al. Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle 2007; 6:2386-92.
32. Shangary S, Wang SM. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 2008; 14:5318-24.
33. Koblish HK, et al. Benzodiazepinedione inhibitors of the Hdm2: p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol Cancer Therap 2006; 5:160-9.
34. Dömling A, Beck B. Preparation of pyrrolylimidazoles as antibiotics and antitumor agents. WO 2001025213.
35. Beck B, Leppert CA, Mueller BK, Dömling A. Discovery of pyrroloimidazoles as agents stimulating neurite outgrowth. QSAR Combin Sci 2006; 25:527-35.
36. Boettcher A, et al. 3-Imidazoyl-indoles for the treatment of proliferative diseases. WO 2008119741.
37. Kussie PH, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274:948-53.
38. Popowicz GM, Czarna A, Holak TA. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 2008; 7:2441-3.
39. Kallen J, et al. Crystal structures of human MdmX HdmX; in complex with p53 peptide-analogues reveal surprising conformational changes. J Biol Chem 2009; 284:8812-21.
40. Hu B, Gilkes DM, Chen J. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 2006; 67:8810-7.
41. Pazgier M, et al. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci USA 2009; 106:4665-70.
42. Zondlo SC, Lee AE, Zondlo NJ. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53. Biochemistry 2006; 45:11945-57.
43. Czarna A, et al. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx. Cell Cycle 2009; 8:1176-84.